Daclatasvir
|
|
|
- CAS-Nr.
- 1009119-64-5
- Englisch Name:
- Daclatasvir
- Synonyma:
- EBP 883;CS-1933;Daklinza;Dakatavir;daclatavir;aclatasvir;Dacaltasvir;Daclatasvir;Dhaka He Wei;Daclatasvir-d16
- CBNumber:
- CB52515028
- Summenformel:
- C40H50N8O6
- Molgewicht:
- 738.88
- MOL-Datei:
- 1009119-64-5.mol
|
Daclatasvir Eigenschaften
- Schmelzpunkt:
- >155oC (dec.)
- Siedepunkt:
- 1071.2±65.0 °C(Predicted)
- Dichte
- 1.249
- storage temp.
- Refrigerator
- L?slichkeit
- Aqueous Acid (Slightly), Chloroform (Sparingly), DMSO (Sparingly), Methanol (Sparingly)
- Aggregatzustand
- Solid
- pka
- 10.92±0.46(Predicted)
- Farbe
- White to Dark Yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| S-S?tze: |
24/25 |
|
|
| HS Code |
29332900 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P330 |
Mund ausspülen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Daclatasvir Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
Definition
ChEBI: Daclatasvir is a member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C. It has a role as a nonstructural protein 5A inhibitor and an antiviral drug. It is a member of biphenyls, a member of imidazoles, a carbamate ester, a carboxamide and a valine derivative. It is a conjugate base of a daclatasvir(2+).
Mechanism of action
Daclatasvir is an inhibitor of NS5A, a phosphoprotein that plays an important role in hepatitis C replication.Daclatasvir reduces serum HCV RNA levels. It disrupts HCV replication by inhibiting viral RNA replication and viral assembly and by inhibiting phosphorylation of NS4A, thereby inhibiting the formation and activation of the HCV replication complex.
Daclatasvir Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Daclatasvir Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 281)Lieferanten
1009119-64-5()Verwandte Suche:
- diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
- Daclatasvir
- EBP 883
- N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
- dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
- Daclatasvir/EBP883
- daclatavir
- DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
- Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
- N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
- Dacaltasvir
- Daklinza
- Daclatasvir-d16
- Dhaka He Wei
- BMS-790052(Daclatasvir)
- Daclatasvir, >=98%
- Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
- BMS-790052;EBP 883;BMS 790052
- CS-1933
- Daclatasvir, 99%, Highly selective HCV NS5A inhibitors
- dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-d
- dimethyl(2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazolChemicalbooke-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
- Daclatasvir 13C2D6Q: What is
Daclatasvir 13C2D6 Q: What is the CAS Number of
Daclatasvir 13C2D6 Q: What is the storage condition of
Daclatasvir 13C2D6 Q: What are the applications of
Daclatasvir 13C2D6
- DaclatasvirQ: What is
Daclatasvir Q: What is the CAS Number of
Daclatasvir Q: What is the storage condition of
Daclatasvir
- C40H50N8O6 Daclatasvir (BMS-790052) 1009119-64-5
- Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
- aclatasvir
- Dakatavir
- Daclatasvir (BMS-790052), HCV NS5A protein inhibitor
- Daclatasvir, 10 mM in DMSO
- Daclatasvir for peak identification
- Daclatasvir for system suitability
- dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
- 1009119-64-5
- 1009119-94-5
- 1029678-59-1
- C40H50N8O6
- C41H52N8O6
- API
- Inhibitors
